{"id":"NCT01624142","sponsor":"Amgen","briefTitle":"Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders","officialTitle":"A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of Evolocumab (AMG145) on LDL-C in Subjects With Severe Familial Hypercholesterolemia","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2012-06-01","primaryCompletion":"2018-05-11","completion":"2018-05-11","firstPosted":"2012-06-20","resultsPosted":"2019-01-28","lastUpdate":"2024-05-28"},"enrollment":300,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Severe Familial Hypercholesterolemia"],"interventions":[{"type":"BIOLOGICAL","name":"Evolocumab","otherNames":["AMG 145","Repatha"]}],"arms":[{"label":"Evolocumab","type":"EXPERIMENTAL"}],"summary":"A study to assess the long term safety and tolerability of evolocumab (AMG 145) in adolescents and adults with severe familial hypercholesterolemia.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"From first dose of study drug in Study 20110271 up to 30 days after the last dose or until the end of study date, whichever was earlier; median duration of treatment was 48.7 months.","effectByArm":[{"arm":"HoFH","deltaMin":94,"sd":null},{"arm":"Severe FH","deltaMin":174,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":44,"countries":["United States","Australia","Belgium","Brazil","Canada","Czechia","France","Greece","Hong Kong","Israel","Italy","Japan","Lebanon","Netherlands","New Zealand","South Africa","Spain","United Kingdom"]},"refs":{"pmids":["28215937","29353350","32057369","38545781","33078867","24014831"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":29,"n":106},"commonTop":["Nasopharyngitis","Influenza","Upper respiratory tract infection","Headache","Myalgia"]}}